North America Diabetes Care Devices Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

North America Diabetes Care Devices Market Segmentation, By Product Type (Blood Glucose Monitoring Devices, Insulin Delivery Devices, Others), By Distribution Channel (Retail Pharmacies, Online Channels, Hospital Pharmacies, Others), By End User (Hospitals & Clinics, Homecare Settings, Diagnostic Centers, Others) - Industry Trends and Forecast to 2032

Diabetes Care Devices Market Size

• The North America Diabetes Care Devices Market size was valued at USD 152.45 Million in 2024 and is expected to reach USD 286.38 Million by 2032, at a CAGR of 7.10% during the forecast period.
• The market growth is largely fueled by the increasing prevalence of diabetes, a growing aging population, and technological advancements in diabetes management.
• Furthermore, rising patient awareness, the availability of user-friendly and advanced devices, and the increasing focus on continuous glucose monitoring and insulin pump therapy are significantly boosting the industry's growth.

Diabetes Care Devices Market Analysis

• Diabetes care devices, including blood glucose meters, continuous glucose monitoring systems, insulin pens, and insulin pumps, are essential tools for managing blood sugar levels and preventing diabetes-related complications. The increasing focus on effective diabetes management and improved patient outcomes is driving the demand for these devices.
• The escalating demand for diabetes care devices is primarily fueled by the rising incidence of diabetes due to factors such as sedentary lifestyles, unhealthy diets, and genetic predisposition. Additionally, the growing awareness of the importance of self-monitoring and advancements in device technology are contributing to market growth.
• U.S. dominates the Diabetes Care Devices Market with the largest revenue share of 32.01% in 2025, characterized by the high prevalence of diabetes and obesity, significant healthcare expenditure, and rapid adoption of advanced technologies like continuous glucose monitoring (CGM) and insulin pumps.
• Canada is expected to be the fastest growing country in the Diabetes Care Devices Market during the forecast period due to a rising diabetes prevalence, increasing public health awareness, and supportive government initiatives for diabetes management.
• Blood Glucose Monitoring Devices segment is expected to dominate the Diabetes Care Devices Market with a market share of 24.2% in 2025, driven by its ease of operation, affordability, and the critical need for frequent self-monitoring among a large and growing diabetic population. This segment benefits from continuous technological advancements that enhance user-friendliness and accuracy, making these devices indispensable for daily diabetes management

Report Scope and Diabetes Care Devices Market Segmentation

Diabetes Care Devices Market Trends

“Integration of Digital Health and Connected Devices”

• A significant and accelerating trend in the North America Diabetes Care Devices Market is the increasing integration of digital health technologies and the development of connected devices. This includes the pairing of blood glucose meters and continuous glucose monitoring systems with smartphone apps and cloud-based platforms for seamless data tracking, analysis, and sharing with healthcare providers.

  • For instance, the latest continuous glucose monitoring (CGM) systems, such as Dexcom G7 and Abbott FreeStyle Libre 3, offer real-time glucose readings directly to smartphones, eliminating the need for routine fingersticks. These systems often include features like customizable alerts, trend analysis, and the ability to share data with caregivers and physicians.

• Furthermore, insulin pumps are becoming increasingly sophisticated, with features like automated insulin delivery (AID) systems, which use algorithms to adjust insulin doses based on real-time glucose data from CGMs. This integration helps in achieving better glycemic control and reducing the risk of hypoglycemia.
• The trend towards connected devices also extends to insulin pens, with the introduction of smart insulin pens that can track doses, calculate bolus amounts, and provide reminders, improving adherence and accuracy in insulin administration.
• This focus on digital health integration is fundamentally reshaping diabetes management in North America, empowering patients with more information and tools for self-care and facilitating better communication with healthcare teams.
• Consequently, major players in the market are heavily investing in research and development to introduce more advanced and connected diabetes care devices that enhance patient convenience and improve clinical outcomes.
• The demand for diabetes care devices with seamless digital connectivity and integration with other health management platforms is expected to continue its rapid growth across North America. 

Diabetes Care Devices Market Dynamics

Driver

“Rising Prevalence of Diabetes and Growing Awareness”

• The increasing prevalence of diabetes across all age groups in North America is a significant driver for the heightened demand for diabetes care devices. According to the Centers for Disease Control and Prevention (CDC), over 37 million adults in the U.S. have diabetes, and this number is projected to rise.

  • For instance, the growing rates of obesity and sedentary lifestyles are contributing to the increasing incidence of type 2 diabetes. Additionally, advancements in diagnostic tools are leading to earlier detection and a larger diagnosed population requiring management.

• Furthermore, there is a growing awareness among patients and healthcare professionals about the importance of proactive diabetes management to prevent long-term complications. This increased awareness is driving the adoption of self-monitoring devices and advanced therapies.
• The availability of educational resources and support programs is also empowering individuals with diabetes to take a more active role in managing their condition, leading to greater demand for user-friendly and effective monitoring and delivery devices.
• The aging population, which is at higher risk of developing diabetes, further contributes to the expanding market for diabetes care devices.
• This escalating prevalence of diabetes and the increasing focus on effective management are expected to continue fueling the growth of the diabetes care devices market in North America.

Restraint/Challenge

“High Cost of Advanced Devices and Reimbursement Issues”

• The high cost associated with advanced diabetes care devices, particularly continuous glucose monitoring (CGM) systems and insulin pumps, poses a significant challenge to broader market access and adoption. The initial investment and ongoing costs of sensors and supplies can be substantial for many individuals, especially those without comprehensive insurance coverage.

  • For instance, the annual cost of CGM therapy can be significantly higher than traditional blood glucose monitoring, making it unaffordable for some patients. Similarly, insulin pumps require a significant upfront investment and regular expenses for consumables.

• Furthermore, complexities and limitations in insurance reimbursement policies for these advanced devices can restrict their availability to a wider patient population. Inconsistent coverage and stringent criteria for eligibility can create barriers to access, hindering market growth.
• Addressing these financial challenges through advocacy for better reimbursement policies, the development of more cost-effective technologies, and patient assistance programs is crucial for ensuring equitable access to advanced diabetes care devices.
• While the clinical benefits of CGM and insulin pumps are well-documented, their high cost remains a significant obstacle for many individuals with diabetes in North America.
• Overcoming these economic barriers will be vital for maximizing the potential of advanced diabetes care devices in improving patient outcomes and reducing the burden of diabetes.

Diabetes Care Devices Market Scope

The market is segmented on the basis of product type, distribution channel, and end user.

• By Product Type

On the basis of product type, the Diabetes Care Devices Market is segmented into Blood Glucose Monitoring Devices (Self-Monitoring Blood Glucose Meters, Testing Strips, Lancets), Insulin Delivery Devices (Insulin Pens, Insulin Syringes, Insulin Pumps), and Others. Blood glucose monitoring devices dominates the largest market revenue share of 24.2% in 2025, driven by the necessity for frequent blood sugar checks among a large patient base. The continuous need for testing strips and lancets also contributes significantly to the revenue of this segment.

The Insulin Delivery Devices segment is anticipated to witness the fastest growth rate of 7.7% from 2025 to 2032, fueled by the rising global prevalence of diabetes, technological advancements leading to more convenient and user-friendly devices (like smart pens and patch pumps), and the increasing adoption of automated insulin delivery systems.

• By distribution channel

On the basis of distribution channel, the Diabetes Care Devices Market is segmented into Retail Pharmacies, Online Channels, Hospital Pharmacies, and Others. Retail pharmacies account for the largest share due to their accessibility and the widespread availability of blood glucose monitoring devices and insulin pens.

Online channels are expected to witness the fastest growth rate, driven by the increasing convenience of purchasing diabetes care devices online, the availability of discounts, and the growing trend of e-commerce in healthcare. Hospital pharmacies also play a crucial role in dispensing devices, particularly insulin pumps and other specialized products, to patients within hospital settings.

• By End User

On the basis of end user, the Diabetes Care Devices Market is segmented into Hospitals & Clinics, Homecare Settings, Diagnostic Centers, and Others. Homecare settings represent the largest end-user segment due to the increasing emphasis on self-management and the growing number of individuals managing their diabetes at home. The availability of user-friendly devices and the rising adoption of telehealth services support this trend.

Hospitals & clinics also constitute a significant end-user segment, particularly for the initiation of insulin pump therapy and the management of complex diabetes cases. Diagnostic centers play a role in providing blood glucose testing services and educating patients on device usage.

Diabetes Care Devices Market Regional Analysis

• U.S. dominates the Diabetes Care Devices Market with the largest revenue share, driven by the high prevalence of diabetes, well-established healthcare infrastructure, and the presence of leading manufacturers. The increasing adoption of advanced technologies like continuous glucose monitoring and insulin pumps further contributes to the market's dominance.
• Consumers in the region benefit from relatively favorable reimbursement policies for diabetes care devices and a strong focus on patient education and self-management.
• This strong market position is also supported by significant investments in research and development, leading to the introduction of innovative and user-friendly diabetes management solutions.

U.S. Diabetes Care Devices Market Insight

The U.S. Diabetes Care Devices Market captured the largest revenue share of 32.01% within North America, fueled by a high incidence of diabetes, widespread adoption of advanced monitoring and insulin delivery systems, and substantial healthcare expenditure. The presence of major market players and continuous technological advancements drive market growth. The increasing focus on personalized diabetes management and the integration of digital health solutions are key trends shaping the U.S. market. 

Canada Diabetes Care Devices Market Insight

The Canada Diabetes Care Devices Market is experiencing steady growth, driven by increasing awareness of diabetes management, government initiatives to improve access to care, and a growing aging population. The adoption of continuous glucose monitoring and insulin pump therapy is rising, contributing to market expansion.

Mexico. Diabetes Care Devices Market Insight

The Mexico Diabetes Care Devices Market is expected to witness significant growth during the forecast period, driven by a rising prevalence of diabetes, increasing healthcare expenditure, and improving access to modern diabetes management technologies. The growing awareness of the importance of blood glucose control is fueling the demand for monitoring devices.  

Diabetes Care Devices Market Share

The Diabetes Care Devices industry is primarily led by well-established companies, including:

• Medtronic (U.S.)
• Abbott (U.S.)
• Dexcom (U.S.)
• Johnson & Johnson (U.S.)
• Insulet Corporation (U.S.)
• Becton, Dickinson and Company (BD) (U.S.)
• Tandem Diabetes Care, Inc. (U.S.)
• Senseonics Holdings, Inc. (U.S.)
• AgaMatrix, Inc. (U.S.)
• Braun Medical Inc. (U.S.)

Latest Developments in North America Diabetes Care Devices Market

• In April 2023, Medtronic announced the U.S. launch of its Simplera Sync™ integrated all-in-one continuous glucose monitor (CGM) and insulin pump. This innovative device simplifies diabetes management by combining continuous glucose sensing and automated insulin delivery in a single, easy-to-use system, aiming to improve glycemic control and reduce the burden of daily management for individuals with diabetes in North America.
• In March 2023, Abbott received FDA clearance for its FreeStyle Libre® 3 system for use in children as young as 2 years old. This expanded indication allows more young individuals with diabetes in North America to benefit from the real-time glucose monitoring capabilities of the FreeStyle Libre 3, aiding in better glucose management and improved quality of life for pediatric patients and their caregivers.
• In March 2023, Insulet Corporation announced the expansion of its Omnipod® 5 Automated Insulin Delivery System to include compatibility with the Dexcom G7 CGM in the U.S. This integration provides users in North America with more options for personalized and automated insulin delivery, enhancing the accuracy and convenience of diabetes management through seamless communication between the pump and CGM.
• In February 2023, Novo Nordisk announced the U.S. availability of its next-generation smart insulin pen, NovoPen® 6. This connected pen records insulin doses and timing, which can be shared with compatible diabetes management apps, helping individuals in North America to track their insulin usage and improve adherence to their treatment plans.
• In January 2023, Dexcom launched its G7 CGM system in Canada, offering individuals with diabetes in North America (specifically Canada in this instance) a smaller, more discreet, and accurate real-time continuous glucose monitoring system with direct-to-smartphone connectivity and enhanced alert customization. This launch aimed to improve the accessibility and user experience of CGM technology in the Canadian market.

SKU-1769